AR046774A1 - LIOFILIZED FORMULATION OF ANTIBODY CONJUGATES - Google Patents

LIOFILIZED FORMULATION OF ANTIBODY CONJUGATES

Info

Publication number
AR046774A1
AR046774A1 ARP040104838A ARP040104838A AR046774A1 AR 046774 A1 AR046774 A1 AR 046774A1 AR P040104838 A ARP040104838 A AR P040104838A AR P040104838 A ARP040104838 A AR P040104838A AR 046774 A1 AR046774 A1 AR 046774A1
Authority
AR
Argentina
Prior art keywords
liofilized
formulation
antibody conjugates
antibody
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Suspension/Interruption
Application number
ARP040104838A
Other languages
Spanish (es)
Inventor
Patrick Garidel
Nicole Denkinger
Christian Berger
Stefan Bassarab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2003161598 external-priority patent/DE10361598A1/en
Priority claimed from DE102004014783A external-priority patent/DE102004014783A1/en
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR046774A1 publication Critical patent/AR046774A1/en
Suspension/Interruption legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composiciones farmacéuticas liofilizadas de anticuerpos, preferiblemente de anticuerpos que están conjugados con una molécula de efector. En particular, se refiere a formulaciones liofilizadas estables de complejos de anticuerpo-DM1. Además, se refiere a procedimientos para la liofilización de complejos de anticuerpo-DM1. Uso de dicha composición para el tratamiento de una enfermedad cancerigena.Lyophilized pharmaceutical compositions of antibodies, preferably antibodies that are conjugated to an effector molecule. In particular, it refers to stable lyophilized formulations of antibody-DM1 complexes. In addition, it refers to procedures for lyophilization of antibody-DM1 complexes. Use of said composition for the treatment of a cancer disease.

ARP040104838A 2003-12-24 2004-12-22 LIOFILIZED FORMULATION OF ANTIBODY CONJUGATES Suspension/Interruption AR046774A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2003161598 DE10361598A1 (en) 2003-12-24 2003-12-24 The freeze-dried pharmaceutical composition as the conjugate of an antibody with a mytansinoid, for the treatment of cancers, is set to a given concentration and pH value before freeze drying
DE102004014783A DE102004014783A1 (en) 2004-03-24 2004-03-24 The freeze-dried pharmaceutical composition as the conjugate of an antibody with a mytansinoid, for the treatment of cancers, is set to a given concentration and pH value before freeze drying

Publications (1)

Publication Number Publication Date
AR046774A1 true AR046774A1 (en) 2005-12-21

Family

ID=34751258

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104838A Suspension/Interruption AR046774A1 (en) 2003-12-24 2004-12-22 LIOFILIZED FORMULATION OF ANTIBODY CONJUGATES

Country Status (3)

Country Link
AR (1) AR046774A1 (en)
TW (1) TW200533375A (en)
WO (1) WO2005065709A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361599A1 (en) * 2003-12-24 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Liquid formulation of antibody conjugates
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
GB201220889D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating metastasizing cancers
GB201220901D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating pancreatic cancer
GB201220891D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating breast cancers
AU2014248640B2 (en) 2013-03-13 2018-03-01 Seagen Inc. Cyclodextrin and antibody-drug conjugate formulations
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
BR112021015034A2 (en) 2019-02-18 2021-10-05 Eli Lilly And Company THERAPEUTIC ANTIBODY FORMULATION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE10361599A1 (en) * 2003-12-24 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Liquid formulation of antibody conjugates

Also Published As

Publication number Publication date
TW200533375A (en) 2005-10-16
WO2005065709A2 (en) 2005-07-21
WO2005065709A3 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
CY1124844T1 (en) PHARMACEUTICAL ANTIBODY PREPARATION
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
DE602004027888D1 (en) ANTI-CD70 ANTIBODY MEDICAMENT CONJUGATES AND THEIR
AR069903A1 (en) ANTIBODY CONJUGATE - ASSOCIATED MOLECULA DIRECTED TO THE PROTEIN TIROSINA QUINASA 7 (PTK 7), PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, NUCLEIC ACID, EXPRESSION FACTOR AND RELATED HUMAN CELL AND ITS USE TO PREPARE A MEDICATION
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
CY1112682T1 (en) Active IL-18 Protein Conjugates and their Medical Uses
PA8626201A1 (en) CALIQUEAMYCIN CONJUGATES
CY1119968T1 (en) COMPOSITIONS OF INNOVATIVE COSMETIC AND / OR PHARMACEUTICAL PRODUCTS AND THEIR USES
AR035977A1 (en) IMMUNOCONJUGADOS OF ANTIBODIES CD44 CITOTOXICOS.
BRPI0409133B8 (en) stable pharmaceutical preparations comprising methylnaltrexone
ECSP077261A (en) HER2 ANTIBODY COMPOSITION
AR032204A1 (en) CYCLODEXTRINE-DROSPIRENONE INCLUSION COMPLEXES
BR0116587A (en) Use of an erythropoietin, pharmaceutical composition, methods for protecting, maintaining or enhancing the viability of a cell, tissue or organ isolated from a mammalian body, to facilitate trancitosis of a molecule through a cellular endothelial barrier in a mammal, composition for transport. a molecule via trancitose through a cellular endothelial barrier, and, composition
AR069747A1 (en) ANTI-B7H4 MONOCLONAL ANTIBODY CONJUGATE - PHARMACO AND METHODS OF USE
WO2004010957A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
ATE492290T1 (en) SACCHARIDE CONJUGATE VACCINES
CL2008001984A1 (en) Anti-cd20 antibody formulation; and its use to treat diseases involving cd20-expressing cells in a mammal.
UY27943A1 (en) COMPOSITIONS AND METHODS TO TREAT CRNCER USING ANTIBODY IMMUNOCATE PLAYS FOR CD44 CYTOTNXICS AND CHEMOTHERAPCUTIC AGENTS
ATE478094T1 (en) ANTIBODIES MOLECULES SPECIFIC TO THE FIBROBLAST ACTIVATION PROTEIN AND IMMUNE CONJUGATES CONTAINING THEM
CR9745A (en) ANTI-B7RP1 HUMAN NEUTRALIZING ANTIBODIES
MA30474B1 (en) FORMULATIONS OF MOLECULE PEPTIDE (S) - LYOPHILIZED THERAPEUTIC ANTIBODY.
GT200600001A (en) USE OF CYANINE COLORS FOR THE DIAGNOSIS OF PROLIFERATIVE DISEASES
CY1108532T1 (en) UNIONS AND COMPOSITIONS FOR PROVIDING ACTIVE AGENTS
CL2008003537A1 (en) 2-aminopyrimidine derived compounds, h4 receptor antagonists; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound in the treatment of an allergic, immunological or inflammatory disease or pain.
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition

Legal Events

Date Code Title Description
FB Suspension of granting procedure